PMC8767018_01
PMC8767018_02
PMC8767018_03
PMC8767018_04
PMC8767018_05
Observed values for Urinary Oxalate/creatinine ratio from the last measurement before lumasiran to Month 18. ULN denotes upper limit of the normal range.
fped-09-791616-g0001.jpg
PMC8767018_05_fped-09-791616-g0001.jpg
F1
The patient showed a rapid and sustained decrease in urinary oxalate/creatinine ratio (see Figure 1). During the 18 months follow-up period, urinary oxalate remained low reaching nearly normal values (see Figure 1).
Observed values for Plasma Oxalate from the last measurement before lumasiran to Month 18. ULN denotes upper limit of the normal range.
fped-09-791616-g0002.jpg
PMC8767018_05_fped-09-791616-g0002.jpg
F2
Normal plasma oxalate levels were reached immediately after the first dose and the values remained consistently low during the 18 months follow-up period (see Figure 2).
PMC8767018_06